Lumibird Shares Drop 3.67% Amid Market Downturn Due to US-Iran Tensions
In a context of high global volatility, European markets faced significant corrections on Thursday, driven by escalating tensions between Washington and Tehran. Technology and industrial sectors were among the hardest hit, dragging down several small and medium-sized capitalizations listed in Paris.
Significant Drop in Lumibird Shares Amidst Global Market Strain
LUMIBIRD shares fell by 3.67% to €21 this Thursday, after closing at €21.80 the previous day. This movement occurs on a particularly challenging day for global markets: the verbal and military escalation between the United States and Iran—following an Iranian denial of a ceasefire mentioned by Donald Trump—has reignited risk aversion across financial markets. This climate broadly impacts technology and growth stocks. ASML Holding, for instance, is down by 4.82%, and Schneider Electric by 4.48%, illustrating the extent of sectoral pressure. In this context, LUMIBIRD's decline is consistent with the overall movement, with no specific catalyst identifiable at the company level. Technically, the stock is trading below its 50-day moving average of €22.52, indicating an unfavorable short-term dynamic. However, with an RSI at 50, the stock is neither in an oversold nor overbought zone, suggesting no clear directional signal at this stage.
Ongoing Correction in a Context of Progressive Pressure
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The ongoing correction is part of a sequence of progressive pressure: LUMIBIRD has lost 2.78% over the past week and 6.67% over the past month. Over three months, the decline remains limited to 0.94%, while the performance over a year is still spectacular at 101%, reflecting a remarkable stock market journey since April 2025. The next key dates for the company are scheduled for April 27, 2026, with the publication of the Q1 2026 revenue, followed by the general meeting the next day. These events could provide investors with tangible elements to reassess the operational fundamentals of the group, which specializes in laser technologies. Regarding the VIX, the implied volatility indicator of the American markets stands at 25.25 points, significantly relaxed from the 30.61 points recorded at the end of last week, but still indicative of high tension. This environment continues to weigh on high-growth stocks, particularly those in the photonics sector.
SectorMachines et équipements industriels›Photonique / lasers / instrumentation optique
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 114,7 millions d'euros
Quarterly revenue: 114,7 millions d'euros
Revenue growth: 7,4 %
EBITDA: 20 millions d'euros
Net income: 5,1 millions d'euros
Free cash flow: 2,3 millions d'euros
92,6 millions d'euros
Guidance from the release
« La croissance de la division Photonique, la progression de +20,2 % de son EBITDA et le niveau historiquement élevé de son carnet de commandes confortent la confiance du Groupe dans la poursuite de sa trajectoire de croissance rentable » — cession de Lumibird Medical à IPG Photonics prévue au T4 2026 (contrat signé début septembre, conditions suspensives en cours)
Risks mentioned
Recul de -16,2 % des activités Environnement, Topographie et Sécurité (5,2 M€)
Perturbations logistiques et géopolitiques ayant affecté le Médical au premier trimestre
Division Médical en retrait de -1,7 % en zone EMEA
Opportunities identified
Carnet de commandes à un niveau historiquement élevé offrant une excellente visibilité
Medtech Photonique en forte croissance (+58,3 %) sur les applications cardiovasculaires
Montée en puissance des grands programmes Défense & Spatial (+16,5 % à 29,4 M€)
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.